Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0019829 (Hodgkin's disease)
 30,247 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

BCNU is an effective antitumor agent in the treatment of Hodgkin's disease. Forty-seven percent of a group of patients with advanced disease, refractory to combination or sequential-agent chemotherapy, achieved an objective response to BCNU. Bone marrow toxicity was delayed in onset and was dose related. When incorporated into a maintenance program after remission induction with combination chemotherapy, BCNU appeared to delay, but not ultimately prevent, relapses during a 2-year followup period. Toxic effects associated with BCNU maintenance therapy in this clinical situation were significantly greater than toxic effects associated with no maintenance therapy.
 ...
PMID:BCNU (NSC-409962) in the treatment of advanced Hodgkin's disease: its role in remission induction and maintenance. 78 98

The first results of the management of adult non-Hodgkin lymphoma according to the National Protocol are reported. 164 pts (71 female and 93 male), aged 50 (range 15 to 79 years) were included. 89 pts had lymphomas with intermediate, 34 with low and 24 with high grade malignancy. 65% had advanced stages (III and IV). In the low grade malignancy group 38% were in complete remission and actuarial survival at 20 months was 80%. In the intermediate grade group, stages I and II the corresponding values were 79 and 85%; in the intermediate grade stages III and IV, 58 and 69%, and in the high grade group 61 and 77%. Bone marrow toxicity and infections were the main complications. 32 pts have died, 10 of them with drug toxicity complications.
 ...
PMID:[Malignant lymphomas. Preliminary report of the National Protocol of Antineoplastic Drugs]. 172 58